Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53-Based cyclotherapy: exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapy

14 Nov 2013

Abstract excerpt

Side effects of chemotherapy are a major impediment in the treatment of cancer. Cyclotherapy is an emerging therapeutic strategy for protecting normal cells from the side effects of chemotherapy. Low, non-genotoxic doses of known p53 activators can be used to induce p53-dependent cell cycle arrest in normal cells bearing wild-type p53. This cytostatic effect of p53 can protect normal cells from the toxicity of S-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cancer Research and Treatments
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24231949
DOI: 10.1038/bjc.2013.702

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53-Based cyclotherapy: exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapyPMID 24231949Read ↗

Role of p53 in breast cancer progression: An insight into p53 targeted therapy.Semantic proximity Read ↗

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapySemantic proximity Read ↗

Strategies for therapeutic targeting of the p53 pathway in cancer.Semantic proximity Read ↗

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy.Semantic proximity Read ↗

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cellsSemantic proximity Read ↗

Dysregulation of P53 in breast cancer: Causative factors and treatment strategies.Semantic proximity Read ↗

Targeting p53 for Novel Anticancer TherapySemantic proximity Read ↗

Targeting p53 for enhanced radio- and chemo-sensitivity.Semantic proximity Read ↗

A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53Semantic proximity Read ↗

Curing cancer with p53.Semantic proximity Read ↗

Pharmacological activation of the p53 pathway in haematological malignanciesSemantic proximity Read ↗

Restoration of p53 to limit tumor growth.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.